{"entity":{"id":"nct05451602","kind":"trial","name":"HEC169096 in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of HEC169096 in advanced solid tumours, run by Sunshine Lake Pharma Co., Ltd., now recruiting.","summary":"HEC169096 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05451602 by Sunshine Lake Pharma Co., Ltd., with 456 participants planned, started 2022-10-21 and due to reach its primary completion in 2026-12-30. Interventions recorded: HEC169096.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05451602","url":"https://clinicaltrials.gov/study/NCT05451602"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["sunshine-lake-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05451602","phase":"1/2","setting":"Phase 1/2 Study of the Highly-selective RET Inhibitor,HEC169096 in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","sponsor":"Sunshine Lake Pharma Co., Ltd.","enrolled":456,"outcomes":[]},"route":"/trials/nct05451602/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"sunshine-lake-pharma","kind":"company","name":"Sunshine Lake Pharma (HEC)","route":"/companies/sunshine-lake-pharma/"}]}}